Target Molecules and their Respective Pathogenic and Protective Antibodies in Myasthenia Gravis.

Target Molecules and their Respective Pathogenic and Protective Antibodies in Myasthenia Gravis. - Target Molecules in MG

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36848

Enrollment

Registered

2008-07-28

Start date

2008-08-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age: 18 years and older For patients with MG: scheduled for a thymectomie using the Da Vinci Robot For control patients: scheduled for a thoracic operation using the Da Vinci Robot for a disorder that is not related to an autoimmune disease or disease affecting the muscles

Exclusion criteria

Exclusion criteria: minors or incapacitated persons not willing to give informed consent

Design outcomes

Primary

Measure	Time frame
The production of 6 monoclonal antibody producing cell lines. The antibodies produced by this cell line will be used for the identification of new autoantigens and the development of new neuroprotective antibodies.	—

Countries

Netherlands

Outcome results